FDA opens formal investigation into cancer risk of Novartis’ Zolgensma and Itvisma gene therapies
The U.S. Food and Drug Administration issued a safety communication on November 6, 2026 confirming that the viral vector in Zolgensma has integrated near cancer‑driving genes in a subset of patients, resulting in confirmed tumors in at least two children. The agency is now formally investigating whether the same insertional oncogenesis risk extends to Itvisma, the newer intrathecal version of the therapy. Novartis disclosed nine tumor reports linked to Zolgensma, three of which involve the GLI1 oncogene, and said more than 6,000 patients have been treated worldwide.
Why it matters
The FDA’s investigation could lead to updates to prescribing information, additional monitoring requirements, or further regulatory action, which may pressure Novartis’ stock and affect market perception of AAV gene‑therapy platforms.
Key facts
- 1The FDA released a safety communication on November 6, 2026 confirming vector integration near cancer‑driving genes in Zolgensma patients. techtimes.com
- 2Novartis disclosed nine tumor reports on November 5, 2026, with two cases showing direct molecular evidence of vector integration. techtimes.com
- 3Three of the nine tumor cases involved activation of the GLI1 oncogene. techtimes.com
- 4More than 6,000 patients have been treated with Zolgensma worldwide. oncodaily.com
- 5Novartis reported combined Zolgensma Group sales of $1.071 billion in the first nine months of 2026. techtimes.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.